TSE:ONC

Oncolytics Biotech Competitors

C$3.72
+0.02 (+0.54 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
C$3.51
Now: C$3.72
C$3.77
50-Day Range
C$3.37
MA: C$4.25
C$5.80
52-Week Range
C$1.81
Now: C$3.72
C$6.06
Volume165,432 shs
Average Volume308,316 shs
Market CapitalizationC$196.30 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Oncolytics Biotech (TSE:ONC) Vs. APS, BU, BLU, TH, NRI, and PLI

Should you be buying ONC stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Oncolytics Biotech, including Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

Aptose Biosciences (TSE:APS) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Aptose Biosciences and Oncolytics Biotech's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.85)-7.58
Oncolytics BiotechN/AN/AN/AC($0.56)-6.64

Aptose Biosciences is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aptose Biosciences and Oncolytics Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Oncolytics BiotechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aptose Biosciences and Oncolytics Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Oncolytics Biotech01202.67

Aptose Biosciences currently has a consensus price target of C$12.00, suggesting a potential upside of 87.21%. Oncolytics Biotech has a consensus price target of C$6.00, suggesting a potential upside of 61.29%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Oncolytics Biotech.

Oncolytics Biotech (TSE:ONC) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Oncolytics Biotech and Burcon NutraScience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/AN/AC($0.56)-6.64
Burcon NutraScienceC$12,045.0045,792.46C$107,101.00C$0.005,150.00

Burcon NutraScience has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Oncolytics Biotech and Burcon NutraScience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncolytics Biotech01202.67
Burcon NutraScience00103.00

Oncolytics Biotech currently has a consensus price target of C$6.00, suggesting a potential upside of 61.29%. Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 2.91%. Given Oncolytics Biotech's higher probable upside, equities research analysts clearly believe Oncolytics Biotech is more favorable than Burcon NutraScience.

Profitability

This table compares Oncolytics Biotech and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncolytics BiotechN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Summary

Burcon NutraScience beats Oncolytics Biotech on 4 of the 6 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and recommmendations for BELLUS Health and Oncolytics Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
Oncolytics Biotech01202.67

Oncolytics Biotech has a consensus target price of C$6.00, suggesting a potential upside of 61.29%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than BELLUS Health.

Profitability

This table compares BELLUS Health and Oncolytics Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
Oncolytics BiotechN/AN/AN/A

Valuation & Earnings

This table compares BELLUS Health and Oncolytics Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$15,000.0029,872.51C$-42,145,306.00C($0.54)-10.63
Oncolytics BiotechN/AN/AN/AC($0.56)-6.64

Oncolytics Biotech has lower revenue, but higher earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Theratechnologies (TSE:TH) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for Theratechnologies and Oncolytics Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
Oncolytics Biotech01202.67

Theratechnologies presently has a consensus target price of C$3.75, suggesting a potential downside of 17.04%. Oncolytics Biotech has a consensus target price of C$6.00, suggesting a potential upside of 61.29%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Theratechnologies.

Profitability

This table compares Theratechnologies and Oncolytics Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
Oncolytics BiotechN/AN/AN/A

Earnings and Valuation

This table compares Theratechnologies and Oncolytics Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$66.05 million6.47C$-34,907,769.00C($0.37)-12.25
Oncolytics BiotechN/AN/AN/AC($0.56)-6.64

Oncolytics Biotech has lower revenue, but higher earnings than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Oncolytics Biotech beats Theratechnologies on 4 of the 6 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Oncolytics Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.28C$-6,980,844.00C($0.61)-57.54
Oncolytics BiotechN/AN/AN/AC($0.56)-6.64

Oncolytics Biotech has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Oncolytics Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
Oncolytics BiotechN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and Oncolytics Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
Oncolytics Biotech01202.67

Oncolytics Biotech has a consensus target price of C$6.00, suggesting a potential upside of 61.29%. Given Oncolytics Biotech's higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Summary

Oncolytics Biotech beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 4 of the 6 factors compared between the two stocks.

ProMetic Life Sciences (TSE:PLI) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares ProMetic Life Sciences and Oncolytics Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
Oncolytics BiotechN/AN/AN/AC($0.56)-6.64

Oncolytics Biotech has lower revenue, but higher earnings than ProMetic Life Sciences. Oncolytics Biotech is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProMetic Life Sciences and Oncolytics Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
Oncolytics BiotechN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for ProMetic Life Sciences and Oncolytics Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Oncolytics Biotech01202.67

Oncolytics Biotech has a consensus target price of C$6.00, suggesting a potential upside of 61.29%.


Oncolytics Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
APS
Aptose Biosciences
1.3$6.41+7.2%C$569.75 millionN/A-7.58Gap Down
BU
Burcon NutraScience
1.2$5.15+2.5%C$551.57 millionC$12,045.005,150.00
BLU
BELLUS Health
0.5$5.72+3.7%C$448.09 millionC$15,000.00-10.63Gap Up
Theratechnologies logo
TH
Theratechnologies
0.7$4.52+0.4%C$427.60 millionC$66.05 million-12.25Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.28+0.9%C$401.71 millionC$76.09 million-57.54
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
MDNA
Medicenna Therapeutics
0.5$5.00+0.6%C$264.51 millionN/A-16.18
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.48+3.4%C$244.93 millionC$52.78 million-1.10Gap Down
IMV logo
IMV
IMV
1.2$3.48+1.7%C$239.70 millionC$3,000.00-6.02
FRX
Fennec Pharmaceuticals
0.5$8.08+7.1%C$210.10 millionC$170,000.00-8.43
RVX
Resverlogix
0.7$0.89+1.1%C$208.25 millionN/A80.91Upcoming Earnings
Gap Down
ATE
Antibe Therapeutics
1.3$4.44+2.5%C$202.05 millionC$9.33 million-5.64Gap Down
HBP
Helix BioPharma
0.5$0.90+0.0%C$127.02 millionN/A-16.36Gap Down
IPA
ImmunoPrecise Antibodies
0.4$12.56+2.8%C$123.03 millionC$17.18 million-58.69Gap Down
ACST
Acasti Pharma
0.8$0.51+7.8%C$88.79 millionC$81,000.0015.00Gap Up
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.62+1.6%C$67.86 millionC$11.64 million-12.16News Coverage
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.33+6.1%C$58.80 millionC$123,870.00-25.38
PMN
ProMIS Neurosciences
0.5$0.19+5.4%C$56.60 millionC$1,787.00-9.25
COV
Covalon Technologies
0.6$1.32+3.0%C$37.44 millionC$23.84 million-5.55News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.26+5.9%C$34.02 millionC$13.02 million-0.37Gap Up
IGX
IntelGenx Technologies
0.9$0.60+5.0%C$30.87 millionC$1.54 million-7.41
QPT
Quest PharmaTech
0.8$0.11+13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74+5.4%C$21.65 millionC$16.14 million22.42Gap Up
CTX
Crescita Therapeutics
0.6$0.85+1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.17+3.0%C$14.12 millionC$1.34 million-4.71Gap Down
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.09+11.8%C$12.70 millionN/A-3.86High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.07+7.7%C$11.06 millionC$2.03 million-1.51
MPH
Medicure
0.7$1.61+1.9%C$10.80 millionC$12.71 million-1.04
BTI
Bioasis Technologies
0.7$0.34+13.2%C$10.16 millionC$4.12 million30.91High Trading Volume
Gap Up
HEM
Hemostemix
0.6$0.37+1.4%C$9.07 millionN/A-2.20
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.40+7.6%C$6.94 millionC$5.60 million7.31Gap Down
IOT
Innovotech
0.8$0.16+6.3%C$6.52 millionC$1.04 million80.00
BCT
BriaCell Therapeutics
0.5$4.10+2.4%C$4.48 millionN/A-1.32
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.18+0.0%C$0.00C$267.59 million50.75News Coverage
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.